Innovatus Life Sciences Acquisition Corp.
- Life Sciences, Technology, Healthcare
David Schiff, our Chief Executive Officer and Chairman since our inception, has served as a Partner at Innovatus Capital Partners, LLC, a private investment firm, since its inception in October 2015. Mr. Schiff has over twenty-five years of experience developing and investing in asset-backed and structured products. From February 2008 to January 2016, Mr. Schiff was a Partner at Perella Weinberg Partners, a global financial services firm focused on investment banking advisory services, where he served as the Portfolio Manager of the Asset Based Value Funds. Prior to joining Perella Weinberg Partners, Mr. Schiff was the CEO and CIO of Broadworth Capital, an asset-backed focused investment vehicle for two high net worth families in 2007. In 2006, he was a Managing Director at Amaranth Advisors, where he was responsible for the construction of its non-mortgage Asset Backed Securities (“ABS”) portfolio, and subsequently oversaw the liquidation of that portfolio. From 2003 to 2005, Mr. Schiff was a Director at Wachovia Securities, where he was responsible for developing various structured principal finance opportunities. From 1993 to 2001, Mr. Schiff held various senior management positions while he was at JPMorgan in the ABS and Securitization groups. Mr. Schiff currently serves on the Board of Directors of Flagship Marine Ventures LLC, a shipping business focused on the long range product tankers, Infinity Transportation III LLC, a railcar and intermodal leasing business, and White Pine Trading LLC, a diamond trading business. Mr. Schiff received a B.S. with distinction in Consumer Economics and Housing from Cornell University. Mr. Schiff is well qualified to serve as a director because of his extensive investing experience.
Andrew Hobson, our Chief Financial Officer and a director since our inception, has served as a Partner and Chief Financial Officer at Innovatus Capital Partners, LLC, a private investment firm, since January 2016. From 1994 to 2015, Mr. Hobson served in various roles at Univision Communications Inc. (“Univision”), a media company, including Senior Executive Vice President and Chief Financial Officer from October 2007 through February 2015, during which time he was responsible for all financial aspects of the company. Prior to his employment at Univision, Mr. Hobson served as a Principal at Chartwell Partners LLC from 1990 to 1994. Mr. Hobson has served as chairman of the board of directors of Cumulus Media, Inc. since June 2018, and on the board of directors of Clear Channel Outdoor Holdings, Inc., since April 2019. Mr. Hobson holds a B.S.E. in both Finance and Accounting, magna cum laude, from University of Pennsylvania—The Wharton School. Mr. Hobson is well qualified to serve as a director because of his extensive experience with public companies and background in finance and accounting.
Claes Ekstrom, our Chief Business Officer since our inception, has served as Managing Director, Head of Life Sciences, at Innovatus Capital Partners, LLC, a private investment firm, since January 2016. Mr. Ekstrom has over 24 years of experience in asset-backed investing, mergers & acquisitions and corporate finance across healthcare and various other industries. From April 2011 to January 2016, Mr. Ekstrom was a member of the Perella Weinberg Partners’ Asset Based Value Strategy Investment Team, where he focused on corporate, healthcare, and consumer opportunities. From 2009 to 2011, Mr. Ekstrom was a Managing Director at Bentley Associates, a boutique investment bank focusing on middle market M&A and private placements. From 2007 to 2009, Mr. Ekstrom served as a Director in the M&A group at Merrill Lynch & Co. From 2004 to 2007, Mr. Ekstrom was a Senior Vice President of the healthcare investment banking group at Lehman Brothers, where he provided M&A and financing advice to leading healthcare companies and healthcare investors. Mr. Ekstrom started his investment banking career with Merrill Lynch & Co. in 1996 and was a member of the M&A group where he executed M&A transactions across a wide range of industries. Mr. Ekstrom received a M.Sc. in Economics and Business Administration from the Stockholm School of Economics.
Luis Diaz, M.D. will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. Since December 2016, Dr. Diaz has served as Head of the Division of Solid Tumor Oncology at the Memorial Sloan Kettering Cancer Center, where he specializes in the treatment of advanced pancreatic and colorectal cancers and directs the Precision and Prevention & Interception Program. Dr. Diaz has founded several healthcare companies focused on cancer therapy and diagnostics including: Sysmex Inostics, Inc., a molecular diagnostic company that is a pioneer in blood-based cell-free tumor DNA (ctDNA) mutation detection in oncology, which he founded in 2008; Personal Genome Diagnostics (“PGDx”), a private company developing regulated tissue-based and non-invasive biopsy genomic products for laboratories, where he has served as a Chairman of the Board of Directors since he founded it in 2010; and PapGen (Thrive), a molecular diagnostic company dedicated to advancing the early detection of cancer, which he founded in 2014. Prior to Memorial Sloan Kettering Cancer Center, from July 2004 to December 2016, Dr. Diaz was a member of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and the head of the Swim Across America Laboratory at Johns Hopkins. Dr. Diaz is currently a member of the board of directors of Jounce Therapeutics, Inc. (NASDAQ:JNCE), a publicly traded immune-oncology company. Dr. Diaz received his undergraduate and medical degrees from the University of Michigan and completed his post-doctoral training at Johns Hopkins University. Dr. Diaz is well qualified to serve as a director because of his extensive experience in the life sciences industry and in developing startup life sciences companies.
Geoffrey Duyk, M.D., Ph.D. will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. Since October 2017, Dr. Duyk has served as the Managing Partner of Circularis LP, a group focused on supporting technology-enabled companies that advance the circular economy and promote sustainability as well as resource efficiency, where he leads the partnership investment in late stage venture/early stage growth technology enabled companies and actively supports portfolio companies as a director. Prior to founding Circularis LP, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies/TPG Biotechnology, a technology focused investment firm (together with its affiliates, “TPG”), from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc. (“Exelixis”), a biotechnology company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals (“Millennium Pharmaceuticals”), from 1993 to 1996. Before his employment at Millennium Pharmaceuticals, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Amyris (Nasdaq: AMRS), Anuvia Plant Nutrients; Concentric Ag Corporation (formerly Inocucor Technologies, Inc.); and ReGen Holdings Limited as well as on the nonprofit Case Western Reserve University Board of Trustees. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. Dr. Duyk serves as a member of Scientific Advisory Boards for HudsonAlpha, and Lawrence Berkeley National Laboratory (DOE). Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and a Ph.D. in Biochemistry and M.D. from Case Western Reserve University. Dr. Duyk is well qualified to serve as a director because of his experience within the biotechnology industry.
R. Erik Holmlin, Ph.D. will be one of our independent directors as of the effective date of the registration statement of which this prospectus forms a part. Dr. Holmlin has served as President and Chief Executive Officer and as a member of the board of directors for Bionano Genomics, Inc., a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business, since January 2011. From June 2010 to February 2011, Dr. Holmlin served as president and Chief Executive Officer of GenVault Corporation, a private biosample management solutions company. Previously, Dr. Holmlin held positions as an entrepreneur in residence at Domain Associates, a life sciences venture capital firm; Chief Commercial Officer of Exiqon A/S, a publicly traded RNA research solutions company; founder and executive at GeneOhm Sciences, which was acquired by Becton Dickinson and Company; and a National Institutes of Health postdoctoral fellow at Harvard University. Until June 2016, Dr. Holmlin served as a director of Nanosphere, Inc., a publicly traded molecular diagnostic company, which was subsequently acquired by Luminex Corporation, a publicly traded biological testing company. Dr. Holmlin received his bachelor’s degree in chemistry from Occidental College, his Ph.D. in chemistry from the California Institute of Technology and MBAs from University of California, Berkeley and Columbia University. Dr. Holmlin is well qualified to serve as a director because of his experience within the biotechnology industry.